News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Job Trends
Novalar Pharmaceuticals, Inc. Plans Shutdown Following Sale of OraVerse to Septodont, to Cut 12 Jobs
March 23, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Xconomy -- It turns out that Novalar Pharmaceuticals’ decision to sell OraVerse, its dental anesthesia reversal agent, was only half the story.
Twitter
LinkedIn
Facebook
Email
Print
Job creations
MORE ON THIS TOPIC
Job Trends
Biopharma cuts at manufacturing plants expected to affect 4,000+
October 29, 2026
·
5 min read
·
Angela Gabriel
Job Trends
8 companies hiring in New York
October 29, 2026
·
1 min read
·
Angela Gabriel
Job Trends
Behind the scenes of 3 Big Pharma layoffs
October 28, 2026
·
5 min read
·
Angela Gabriel
Layoffs
After 2 patient deaths and cell therapy durability concerns, Artiva cuts 94% of workforce
October 27, 2026
·
2 min read
·
Angela Gabriel
